Exploring and validating surrogate endpoints in colorectal cancer
- First Online:
- 137 Downloads
Sargent et al (J Clin Oncol 23: 8664–8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484–492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years.
KeywordsSurrogate endpoint Colorectal cancer Surrogate threshold effect
Unable to display preview. Download preview PDF.
- Burzykowski T and Cortiñas Abrahantes J (2005). Validation in case of two failure-time endpoints. In: Burzykowski, T, Molenberghs, G and Buyse, M (eds) Evaluation of Surrogate Endpoints, Springer, New York Google Scholar
- Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P for the Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer (2004) Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 22:484–492Google Scholar
- Sargent DJ for the ACCENT Group (2007) Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800 patient ACCENT dataset. 2007 Gastrointestinal Cancers Symposium, Abstract #274Google Scholar